# PROMID

Source: https://onco.cc/trials/promid/  
OnCo record `promid` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Showed for the first time that a hormone-suppressing injection also slows neuroendocrine tumour growth.

## Summary

PROMID, trial NCT00171873 sponsored by Novartis and the German NET study group and reported in 2009, showed for the first time that a hormone-suppressing somatostatin analogue injection also slows neuroendocrine tumour growth. It randomised 85 patients with treatment-naive metastatic midgut neuroendocrine tumours to octreotide LAR or placebo and met its primary endpoint of time to tumour progression with a large effect, while overall survival did not differ because of crossover and a low event rate. OnCo links it to neuroendocrine tumours and to the somatostatin analogues record, and CLARINET extended the antiproliferative effect to lanreotide across enteropancreatic tumours. Whether starting a somatostatin analogue early changes survival, rather than only delaying progression, remains unproven.

## Fields

- Kind: Trial
- Status: positive
- Last checked: 2026-09-07
- Registry id: NCT00171873
- Phase: 3
- Setting: Treatment-naive metastatic midgut NETs: octreotide LAR vs placebo
- Sponsor: Novartis / German NET study group
- Enrolled: 85
- Result: TTP 14.3 vs 6.0 months, HR 0.34.
- Outcomes: Time to tumour progression: Octreotide LAR 14.3 months vs Placebo 6 months, HR 0.34
- Replication: CLARINET extended the antiproliferative effect to lanreotide across enteropancreatic NETs.

## Sources

- ClinicalTrials.gov NCT00171873: https://clinicaltrials.gov/study/NCT00171873

## Connected records

- cancers: [Neuroendocrine tumours](https://onco.cc/cancers/neuroendocrine/), [Small intestinal neuroendocrine tumours](https://onco.cc/cancers/small-intestinal-net/)
- drugs: [Somatostatin analogues (octreotide, lanreotide)](https://onco.cc/drugs/octreotide-lanreotide/)
- companies: [Novartis](https://onco.cc/companies/novartis/)
- key papers: [PROMID: octreotide LAR in the control of tumour growth in metastatic midgut neuroendocrine tumours](https://onco.cc/key-papers/paper-promid-rinke-jco-2009/)

---
JSON: https://onco.cc/api/v1/entities/promid.json